Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2016

View Archived Issues

Researchers present phase Ib results on Lilly's taladegib for SCLC

Blueprint Medicines discloses preliminary first-in-human data of BLUE-285 in GIST patients

Ropeginterferon alfa-2b shows promise in patients with polycythemia vera

Investigators present phase II results on CTL-019 in ALL patients

Ascendance Biotechnology gains rights to GE Healthcare's Cytiva cardiomyocytes

Achillion Pharmaceuticals receives milestone payment for JNJ-4178

Vertex Pharmaceuticals patents triazoles for demyelinating diseases

Medshine Discovery discloses JAK inhibitors

Galena Biopharma gives update on regulatory plans for GALE-401

Syros Pharmaceuticals describes c-Myc inhibitors

Dana-Farber Cancer Institute develops SMO receptor antagonists

Chiesi Farmaceutici presents muscarinic M3 receptor antagonists and beta2-adrenoceptor agonists

Patient enrollment begins in phase I trial of TQ-B3395 in patients with advanced cancer

EMT gene expression as biomarkers in neuroendocrine lung carcinoma

Shire is enrolling patients in phase III trial of maribavir in transplant recipients

Bristol-Myers Squibb initiates phase II trial of BMS-986165

AstraZeneca initiates phase I trial of AZD-0284 for plaque psoriasis

AstraZeneca studies AZD-8871 for COPD in phase IIa trial

Lilly begins phase I study of LY-2775240

New phase II/III trial investigates Glassia for acute GvHD

Clovis initiates phase II trial of rucaparib for metastatic castration-resistant prostate cancer

Boehringer Ingelheim initiates phase I trial of BI-754091 in solid tumors

Lilly initiates first-in-human study of LY-3209590 for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...